Analyst Thomas Shrader works at BTIG and is covering the the Healthcare sector with 208 price targets and ratings documented since 2014 spanning on 27 stocks. Previously, Thomas Shrader worked at STIFEL.
Thomas Shrader's average stock forecast success ratio is 35.61% with an average time for price targets to be met of 125.89 days.
Most recent stock forecast was given on ATHA, Athira Pharma Inc. at 30-Mar-2023.
Analyst best performing recommendations are on VRNA (VERONA PHARMA PLC).
The best stock recommendation documented was for VRNA (VERONA PHARMA PLC) at 12/20/2022. The price target of $26 was fulfilled within 10 days with a profit of $7.41 (39.86%) receiving and performance score of 39.86.
Average potential price target upside
Currently, out of the existing stock ratings of Thomas Shrader - 9 which are a Buy (100%)
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
29
$15.25 (110.91%)
23
22 days ago
2/7 (28.57%)
$18.63 (72.87%)
146
Buy
27
$13.25 (96.36%)
19
1 months 17 days ago
3/16 (18.75%)
$14.14 (98.01%)
168
Buy
30
$16.25 (118.18%)
80
2 months ago
0/2 (0%)
$17.48 (56.55%)
Buy
18
$4.25 (30.91%)
18
2 months 1 days ago
2/3 (66.67%)
$1.19 (3.42%)
43
Buy
28
$14.25 (103.64%)
80
2 months 23 days ago
1/5 (20%)
$17.99 (40.98%)
65
